First-line Treatment of P53 Mutation With PD-L1 Expression in DLBCL With Anti-PD-1 Mab and R-CHOP

NCT05280626 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

100

Enrollment

INDUSTRY

Sponsor class

Conditions

Diffuse Large B-Cell Lymphoma

Interventions

DRUG: Sintilimab
DRUG: Rituximab

Sponsor

Innovent Biologics (Suzhou) Co. Ltd.